Target therapy is another important option for NSCLC treatment, including the targets on angiogenesis or on cancer cells with epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase gene changes, ROS1 fusion and BRAF gene changes. Here, EGFR is linked to cancer.